This review summarizes the clinical and endocrinologic features of androgenetic alopecia and mentions potential treatments, but it reports no new findings.
110 citations
,
October 2019 in “Translational Andrology and Urology”
This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.
This review discusses the current medical treatments for hepatocellular carcinoma, noting that while new local therapies show high response rates, their true impact on patient survival is uncertain.
April 2022 in “Journal of The American Academy of Dermatology”
This article discusses scalp neuropathy in androgenetic alopecia and suggests that changes in tactile sensation due to Aβ fibers and increased nociception from circ-HTMR may be involved.
AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
Dutasteride may cause chronic infertility by reducing semen volume and motility, with concerns about irreversible prostate fibrosis. Users consider switching to finasteride or using treatments like minoxidil and microneedling, weighing hair preservation against fertility.
Dutasteride at 2.5mg is considered a potential hair loss cure due to its DHT-blocking ability, but there are concerns about side effects and individual responses. Minoxidil, finasteride, and RU58841 are also discussed, with mixed opinions on their effectiveness and safety.
DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.